AbbVie Ireland NL B.V.

To evaluate the efficacy, safety, and tolerability of upadacitinib in adults and adolescents with nonsegmental vitiligo (NSV) who are candidates for systemic therapy.

The primary objective of Phase 1 was to evaluate the efficacy and safety of upadalimumab and adalimumab in adult subjects who were refractory to or intolerant of single TNFi therapy and were receiving background MTX. The objective of Phase 2 was to evaluate the long-term safety, tolerability, and efficacy of upadalimumab and adalimumab in subjects who completed Phase 1.

This program consists of 3 separate studies, with 2 phases in Study 1 and Study 2. The primary objectives of Study 1 and Study 2 are to evaluate the efficacy (how well the treatment works), safety, and tolerability of upadacitinib compared to placebo in Phase A, and to evaluate the efficacy, safety, and tolerability of extended treatment with upadacitinib in Phase B. The primary objective of Study 3 is to evaluate the long-term safety and efficacy of upadacitinib.